Advertisement

Proteomic Analysis of Blood and Pancreatic Juice

  • Mark Aspinall-O’Dea
  • John Neoptolemos
  • Eithne Costello
Chapter

Abstract

The proteome is the complete set of proteins present in a defined cellular or extracellular compartment. A number of studies have been undertaken to characterise the protein profiles of plasma/serum and pancreatic juice, and protein differences between samples from cancer patients and benign disease controls or healthy individuals have been defined. More recently, advances in liquid chromatography-mass spectrometry (LC-MS) instrumentation, as well as developments in quantitative proteomic approaches, and analysis of post-translational modifications have enabled interrogation of cancer pathways and the effects of drugs on those pathways. For targeted drugs to be used effectively, biomarkers that provide information regarding drug activity, toxicity or patient response are essential. Such biomarkers are particularly useful if they can be detected in samples that are readily accessible, such as plasma/serum. The application of proteomic techniques affords opportunities for discovering and evaluating biomarkers that aid the process of drug development. In this chapter, some of the recent advances in proteomic techniques that enable the detection and quantification of proteins in blood and pancreatic juice will be reviewed. Particular emphasis will be placed on the significance of these advances for novel treatments of pancreatic cancer.

Keywords

Vascular Endothelial Growth Factor Epidermal Growth Factor Receptor Pancreatic Cancer Pancreatic Juice Pancreatic Cancer Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Anderson NG, Ahmad T, Chan K et al (2001) ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression. Int J Cancer 94:774–782CrossRefPubMedGoogle Scholar
  2. Aspinall-O’Dea M, Costello E (2007) The pancreatic cancer proteome – recent advances and future promise. Proteomics Clin Appl 1:1066–1079CrossRefGoogle Scholar
  3. Barker AJ, Gibson KH, Grundy W et al (2001) Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 11:1911–1914CrossRefPubMedGoogle Scholar
  4. Barton CM, Hall PA, Hughes CM et al (1991) Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol 163:111–116CrossRefPubMedGoogle Scholar
  5. Batchelor TT, Sorensen AG, di Tomaso E et al (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95CrossRefPubMedGoogle Scholar
  6. Bielenberg DR, Klagsbrun M (2007) Targeting endothelial and tumor cells with semaphorins. Cancer Metastasis Rev 26:421–431CrossRefPubMedGoogle Scholar
  7. Blaszkowsky LS, Ryan DP, Earle C et al (2007) A phase II study of docetaxel in combination with ZD1839 (gefitinib) in previously treated patients with metastatic pancreatic cancer. J Clin Oncol (Meeting Abstracts) 25:15080Google Scholar
  8. Bloomston M, Zhou JX, Rosemurgy AS et al (2006) Fibrinogen gamma overexpression in pancreatic cancer identified by large-scale proteomic analysis of serum samples. Cancer Res 66:2592–2599CrossRefPubMedGoogle Scholar
  9. Camp ER, Yang A, Liu W et al (2006) Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer. Clin Cancer Res 12:2628–2633CrossRefPubMedGoogle Scholar
  10. Cappuzzo F, Hirsch FR, Rossi E et al (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643–655CrossRefPubMedGoogle Scholar
  11. Chen R, Pan S, Yi EC et al (2006) Quantitative proteomic profiling of pancreatic cancer juice. Proteomics 6:3871–3879CrossRefPubMedGoogle Scholar
  12. Chen R, Pan S, Aebersold R et al (2007a) Proteomics studies of pancreatic cancer. Proteomics Clin Appl 1:1582–1591CrossRefGoogle Scholar
  13. Chen R, Pan S, Cooke K et al (2007b) Comparison of pancreas juice proteins from cancer versus pancreatitis using quantitative proteomic analysis. Pancreas 34:70–79CrossRefGoogle Scholar
  14. Ciardiello F, Caputo R, Bianco R et al (2001) Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res 7:1459–1465PubMedGoogle Scholar
  15. Denduluri N, Yang SX, Berman AW et al (2008) Circulating biomarkers of bevacizumab activity in patients with breast cancer. Cancer Biol Ther 7:15–20CrossRefPubMedGoogle Scholar
  16. Deng R, Lu Z, Chen Y et al (2007) Plasma proteomic analysis of pancreatic cancer by 2-dimensional gel electrophoresis. Pancreas 34:310–317CrossRefPubMedGoogle Scholar
  17. Dragovich T, Burris H III, Loehrer P et al (2008) Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial. Am J Clin Oncol 31:157–162CrossRefPubMedGoogle Scholar
  18. Dvorak HF (2002) Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20:4368–4380CrossRefPubMedGoogle Scholar
  19. Ehmann M, Felix K, Hartmann D et al (2007) Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 34:205–214CrossRefPubMedGoogle Scholar
  20. Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:579–591CrossRefPubMedGoogle Scholar
  21. Faca VM, Song KS, Wang H et al (2008) A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 5:e123CrossRefPubMedGoogle Scholar
  22. Fountzilas G, Murray S, Xiros N et al (2007) Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer. A phase II trial. J Clin Oncol (Meeting Abstracts) 25:15016Google Scholar
  23. Friess H, Wang L, Zhu Z et al (1999) Growth factor receptors are differentially expressed in cancers of the papilla of vater and pancreas. Ann Surg 230:767–774; discussion 774–765Google Scholar
  24. Ghaneh P, Costello E, Neoptolemos JP (2007) Biology and management of pancreatic cancer. Gut 56:1134–1152CrossRefPubMedGoogle Scholar
  25. Gorg A, Obermaier C, Boguth G et al (2000) The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 21:1037–1053CrossRefPubMedGoogle Scholar
  26. Grantzdorffer I, Carl-McGrath S, Ebert MP et al (2008) Proteomics of pancreatic cancer. Pancreas 36:329–336CrossRefPubMedGoogle Scholar
  27. Gronborg M, Bunkenborg J, Kristiansen TZ et al (2004) Comprehensive proteomic analysis of human pancreatic juice. J Proteome Res 3:1042–1055CrossRefPubMedGoogle Scholar
  28. Harsha HC, Jimeno A, Molina H et al (2008) Activated epidermal growth factor receptor as a novel target in pancreatic cancer therapy. J Proteome Res 7:4651–4658CrossRefPubMedGoogle Scholar
  29. Hecht JR, Trarbach T, Jaeger E et al (2005) A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). J Clin Oncol (Meeting Abstracts) 23:LBA3Google Scholar
  30. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011–1027CrossRefPubMedGoogle Scholar
  31. Honda K, Hayashida Y, Umaki T et al (2005) Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res 65:10613–10622CrossRefPubMedGoogle Scholar
  32. Kimura K, Sawada T, Komatsu M et al (2006) Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin Cancer Res 12:4925–4932CrossRefPubMedGoogle Scholar
  33. Kindler HL, Friberg G, Singh DA et al (2005) Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 23:8033–8040CrossRefPubMedGoogle Scholar
  34. Klagsbrun M, Takashima S, Mamluk R (2002) The role of neuropilin in vascular and tumor biology. Adv Exp Med Biol 515:33–48PubMedGoogle Scholar
  35. Kobayashi A, Yamaguchi T, Ishihara T et al (2005) Usefulness of plasma vascular endothelial growth factor in the diagnosis of pancreatic carcinoma: differential diagnosis, tumor progression, and patient survival. Pancreas 31:74–78CrossRefPubMedGoogle Scholar
  36. Koehne C, Bajetta E, Lin E et al (2006) Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). J Clin Oncol (Meeting Abstracts) 24:3508Google Scholar
  37. Koopmann J, Zhang Z, White N et al (2004) Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 10:860–868CrossRefPubMedGoogle Scholar
  38. Korc M, Chandrasekar B, Yamanaka Y et al (1992) Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 90:1352–1360CrossRefPubMedGoogle Scholar
  39. Kruse U, Bantscheff M, Drewes G et al (2008) Chemical and pathway proteomics: powerful tools for oncology drug discovery and personalized health care. Mol Cell Proteomics 7:1887–1901CrossRefPubMedGoogle Scholar
  40. Kummar S, Kinders R, Rubinstein L et al (2007) Compressing drug development timelines in oncology using phase ‘0’ trials. Nat Rev Cancer 7:131–139CrossRefPubMedGoogle Scholar
  41. Kuo T, Cabebe EC, Koong A et al (2008) An update of a phase I/II study of the VEGF receptor tyrosine kinase inhibitor vatalanib and gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol (Meeting Abstracts) 26:15571Google Scholar
  42. Lange V, Picotti P, Domon B et al (2008) Selected reaction monitoring for quantitative proteomics: a tutorial. Mol Syst Biol 4:222CrossRefPubMedGoogle Scholar
  43. Liedtke C, Mazouni C, Hess KR et al (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26:1275–1281CrossRefPubMedGoogle Scholar
  44. Lin Y, Goedegebuure PS, Tan MCB et al (2006) Proteins associated with disease and clinical course in pancreas cancer: a proteomic analysis of plasma in surgical patients. J Proteome Res 5:2169–2176CrossRefPubMedGoogle Scholar
  45. Linardou H, Dahabreh IJ, Kanaloupiti D et al (2008) Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9:962–972CrossRefPubMedGoogle Scholar
  46. Loperfido S, Angelini G, Benedetti G et al (1998) Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 48:1–10CrossRefPubMedGoogle Scholar
  47. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139CrossRefPubMedGoogle Scholar
  48. Macek B, Mann M, Olsen JV (2008) Global and site-specific quantitative phosphoproteomics: principles and applications. Annu Rev Pharmacol Toxicol 49:199–221CrossRefGoogle Scholar
  49. Maisey NR, Norman AR, Hill A et al (2005) CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer 93:740–743CrossRefPubMedGoogle Scholar
  50. Marshall J (2006) Clinical implications of the mechanism of epidermal growth factor receptor inhibitors. Cancer 107:1207–1218CrossRefPubMedGoogle Scholar
  51. Masago K, Fujita S, Hatachi Y et al (2008) Clinical significance of pretreatment serum amphiregulin and transforming growth factor-α, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer. Cancer Sci 99:2295–2301CrossRefPubMedGoogle Scholar
  52. Merchant M, Weinberger SR (2000) Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 21:1164–1177CrossRefPubMedGoogle Scholar
  53. Middleton G, Ghaneh P, Costello E et al (2008) New treatment options for advanced pancreatic cancer. Expert Rev Gastroenterol Hepatol 2:673–696CrossRefPubMedGoogle Scholar
  54. Miribel L, Gianazza E, Arnaud P (1988) The use of dye-ligand affinity chromatography for the purification of non-enzymatic human plasma proteins. J Biochem Biophy Methods 16:1–15CrossRefGoogle Scholar
  55. Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966CrossRefPubMedGoogle Scholar
  56. Morabito A, De Maio E, Di Maio M et al (2006) Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 11:753–764CrossRefPubMedGoogle Scholar
  57. Novotny J, Petruzelka L, Vedralova J et al (2001) Prognostic significance of c-erbB-2 gene expression in pancreatic cancer patients. Neoplasma 48:188–191PubMedGoogle Scholar
  58. O’Farrell PH (1975) High resolution two-dimensional electrophoresis of proteins. J Biol Chem 250:4007–4021PubMedGoogle Scholar
  59. Okada N, Ohshio G, Yamaki K et al (1995) Elevated serum c-erbB-2 protein levels in patients with pancreatic cancer: correlation to metastasis and shorter survival. Oncology 52:392–396CrossRefPubMedGoogle Scholar
  60. Ong SE, Mann M (2005) Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol 1:252–262CrossRefPubMedGoogle Scholar
  61. Ong SE, Blagoev B, Kratchmarova I et al (2002) Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 1:376–386CrossRefPubMedGoogle Scholar
  62. Pratesi G, Petrangolini G, Tortoreto M et al (2008) Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu. J Immunother 31:537–544CrossRefPubMedGoogle Scholar
  63. Reckamp KL, Krysan K, Morrow JD et al (2006) A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res 12:3381–3388CrossRefPubMedGoogle Scholar
  64. Reckamp KL, Gardner BK, Figlin RA et al (2008) Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. J Thorac Oncol 3:117–124CrossRefPubMedGoogle Scholar
  65. Ross JS, Fletcher JA, Bloom KJ et al (2004) Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics 3:379–398CrossRefPubMedGoogle Scholar
  66. Rosty C, Christa L, Kuzdzal S et al (2002) Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res 62:1868–1875PubMedGoogle Scholar
  67. Saeki H, Yanoma S, Takemiya S et al (2007) Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer. Oncol Rep 18:433–439PubMedGoogle Scholar
  68. Saxby AJ, Nielsen A, Scarlett CJ et al (2005) Assessment of HER-2 status in pancreatic adenocarcinoma: correlation of immunohistochemistry, quantitative real-time RT-PCR, and FISH with aneuploidy and survival. Am J Surg Pathol 29:1125–1134CrossRefPubMedGoogle Scholar
  69. Schneider MR, Wolf E (2008) The epidermal growth factor receptor ligands at a glance. J Cell PhysiolGoogle Scholar
  70. Schreiber TB, Mausbacher N, Breitkopf SB et al (2008) Quantitative phosphoproteomics—an emerging key technology in signal-transduction research. Proteomics 8:4416–4432CrossRefPubMedGoogle Scholar
  71. Sennels L, Salek M, Lomas L et al (2007) Proteomic analysis of human blood serum using peptide library beads. J Proteome Res 6:4055–4062CrossRefPubMedGoogle Scholar
  72. Shadforth I, Dunkley T, Lilley K et al (2005) i-Tracker: for quantitative proteomics using iTRAQTM. BMC Genomics 6:145CrossRefPubMedGoogle Scholar
  73. Shiio Y, Aebersold R (2006) Quantitative proteome analysis using isotope-coded affinity tags and mass spectrometry. Nat Protoc 1:139–145CrossRefPubMedGoogle Scholar
  74. Sjobring U, Bjorck L, Kastern W (1991) Streptococcal protein G. Gene structure and protein binding properties. J Biol Chem 266:399–405PubMedGoogle Scholar
  75. Smith RA, Bosonnet L, Ghaneh P et al (2008) The platelet-lymphocyte ratio improves the predictive value of serum CA19-9 levels in determining patient selection for staging laparoscopy in suspected periampullary cancer. Surgery 143:658–666CrossRefPubMedGoogle Scholar
  76. Soker S, Takashima S, Miao HQ et al (1998) Neuropilin-1 Is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92:735–745CrossRefPubMedGoogle Scholar
  77. Soker S, Miao H-Q, Nomi M et al (2002) VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J Cell Biochem 85:357–368CrossRefPubMedGoogle Scholar
  78. Suissa A, Yassin K, Lavy A et al (2005) Outcome and early complications of ERCP: a prospective single center study. Hepatogastroenterology 52:352–355PubMedGoogle Scholar
  79. Sultana A, Smith CT, Cunningham D et al (2007) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25:2607–2615CrossRefPubMedGoogle Scholar
  80. Taguchi F, Solomon B, Gregorc V et al (2007) Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study. J Natl Cancer Inst 99:838–846CrossRefPubMedGoogle Scholar
  81. Thompson ST, Cass KH, Stellwagen E (1975) Blue dextran-sepharose: an affinity column for the dinucleotide fold in proteins. Proceedings of the National Academy of Sciences 72:669–672Google Scholar
  82. Tian M, Cui YZ, Song GH et al (2008) Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer 8:241CrossRefPubMedGoogle Scholar
  83. Unlu M, Morgan ME, Minden JS (1997) Difference gel electrophoresis: a single gel method for detecting changes in protein extracts. Electrophoresis 18:2071–2077CrossRefPubMedGoogle Scholar
  84. Vandervoort J, Soetikno RM, Tham TC et al (2002) Risk factors for complications after performance of ERCP. Gastrointest Endosc 56:652–656CrossRefPubMedGoogle Scholar
  85. Vervenne W, Bennouna J, Humblet Y et al (2008) A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer. J Clin Oncol (Meeting Abstracts) 26:4507Google Scholar
  86. Wang YY, Cheng P, Chan DW (2003) A simple affinity spin tube filter method for removing high-abundant common proteins or enriching low-abundant biomarkers for serum proteomic analysis. Proteomics 3:243–248CrossRefPubMedGoogle Scholar
  87. Wedge SR, Kendrew J, Hennequin LF et al (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65:4389–4400CrossRefPubMedGoogle Scholar
  88. Wong HH, Lemoine NR (2008) Biological approaches to therapy of pancreatic cancer. Pancreatology 8:431–461CrossRefPubMedGoogle Scholar
  89. Wood JM, Bold G, Buchdunger E et al (2000) PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60:2178–2189PubMedGoogle Scholar
  90. Wu WW, Wang G, Baek SJ et al (2006) Comparative study of three proteomic quantitative methods, DIGE, cICAT, and iTRAQ, using 2D Gel- or LC-MALDI TOF/TOF. J Proteome Res 5:651–658CrossRefPubMedGoogle Scholar
  91. Yamanaka Y, Friess H, Kobrin MS et al (1993a) Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 13:565–569Google Scholar
  92. Yamanaka Y, Friess H, Kobrin MS et al (1993b) Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol 24:1127–1134CrossRefGoogle Scholar
  93. Yan L, Tonack S, Smith R et al (2009) Confounding effect of obstructive jaundice in the interpretation of proteomic plasma profiling data for pancreatic cancer. J Proteome Res 8:142–148CrossRefPubMedGoogle Scholar
  94. Zolla L (2008) Proteomics studies reveal important information on small molecule therapeutics: a case study on plasma proteins. Drug Discov Today 13:1042–1051CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Mark Aspinall-O’Dea
  • John Neoptolemos
  • Eithne Costello
    • 1
  1. 1.Division of Surgery and Oncology, Royal Liverpool University HospitalUniversity of LiverpoolLiverpool, MerseysideUK

Personalised recommendations